TITLE 18. PROFESSIONAL AND OCCUPATIONAL LICENSING
REGISTRAR'S NOTICE: The
Board of Pharmacy is claiming an exemption from Article 2 of the Administrative
Process Act in accordance with § 2.2-4006 A 13 of the Code of Virginia,
which exempts amendments to regulations of the board to schedule a substance in
Schedule I or II pursuant to subsection D of § 54.1-3443 of the Code of
Virginia. The board will receive, consider, and respond to petitions by any
interested person at any time with respect to reconsideration or revision.
Title of Regulation: 18VAC110-20. Regulations Governing
the Practice of Pharmacy (amending 18VAC110-20-322).
Statutory Authority: §§ 54.1-2400 and 54.1-3443 of the
Code of Virginia.
Effective Date: June 13, 2018.
Agency Contact: Caroline Juran, RPh, Executive Director,
Board of Pharmacy, 9960 Mayland Drive, Suite 300, Richmond, VA 23233-1463,
telephone (804) 367-4456, FAX (804) 527-4472, or email
caroline.juran@dhp.virginia.gov.
Summary:
The amendments add seven compounds into Schedule I of the
Drug Control Act as recommended by the Virginia Department of Forensic Science
pursuant to § 54.1-3443 of the Code of Virginia. The compounds added by this
regulatory action will remain in effect for 18 months or until the compounds
are placed in Schedule I by legislative action of the General Assembly.
18VAC110-20-322. Placement of chemicals in Schedule I.
A. Pursuant to subsection D of § 54.1-3443 of the Code of
Virginia, the Board of Pharmacy places the following in Schedule I of the Drug
Control Act:
1. 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone
(other names: N,N-Dimethylpentylone, Dipentylone);
2. 4-chloro-alpha-Pyrrolidinovalerophenone (other name:
4-chloro-alpha-PVP);
3. 4-methyl-alpha-Pyrrolidinohexiophenone (other name: MPHP);
4. 4-fluoro-alpha-Pyrrolidinoheptiophenone (other name:
4-fluoro-PV8);
5. 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one (other
name: 4-methoxy-PV9);
6. 4-allyloxy-3,5-dimethoxyphenethylamine (other name:
Allylescaline);
7. 4-methyl-alpha-ethylaminopentiophenone; and
8. N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide
(other name: para-fluoroisobutyryl fentanyl).
The placement of drugs listed in this subsection shall remain
in effect until August 22, 2018, unless enacted into law in the Drug Control
Act.
B. Pursuant to subsection D of § 54.1-3443 of the Code of
Virginia, the Board of Pharmacy places the following in Schedule I of the Drug
Control Act:
1. 6-ethyl-6-nor-lysergic acid diethylamide (other name: ETH-LAD),
its optical, position, and geometric isomers, salts, and salts of isomers,
whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation;
2. 6-allyl-6-nor-lysergic acid diethylamide (other name:
AL-LAD), its optical, position, and geometric isomers, salts, and salts of
isomers, whenever the existence of such salts, isomers, and salts of isomers is
possible within the specific chemical designation;
3. Synthetic opioids:
a. N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide
(other name: beta-hydroxythiofentanyl), its isomers, esters, ethers, salts, and
salts of isomers, esters, and ethers, unless specifically excepted, whenever
the existence of these isomers, esters, ethers, and salts is possible within
the specific chemical designation;
b.
N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other
names: 2-fluorofentanyl, ortho-fluorofentanyl), its isomers, esters, ethers,
salts, and salts of isomers, esters, and ethers, unless specifically excepted,
whenever the existence of these isomers, esters, ethers, and salts is possible
within the specific chemical designation; and
c. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-propenamide
(other name: Acryl fentanyl), its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, unless specifically excepted, whenever the
existence of these isomers, esters, ethers, and salts is possible within the
specific chemical designation;
4. Cannabimimetic agents:
a. 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (other
name: SDB-006), its salts, isomers, and salts of isomers whenever the existence
of such salts, isomers, and salts of isomers is possible within the specific
chemical designation; and
b. Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate
(other name: FUB-PB-22), its salts, isomers, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation; and
5. Benzodiazepine: flubromazepam, its salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
The placement of drugs listed in this subsection shall remain
in effect until December 13, 2018, unless enacted into law in the Drug Control
Act.
C. Pursuant to subsection D of § 54.1-3443 of the Code of
Virginia, the Board of Pharmacy places the following in Schedule I of the Drug
Control Act:
1. 4-Bromo-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine
(25B-NBOH), its optical, position, and geometric isomers, salts and salts of
isomers, whenever the existence of such salts, isomers, and salts of isomers is
possible within the specific chemical designation.
2. Methyl
N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA), its salts,
isomers, and salts of isomers whenever the existence of such salts, isomers,
and salts of isomers is possible within the specific chemical designation.
3. N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (Tetrahydrofuran
fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, unless specifically excepted, whenever the existence of these
isomers, esters, ethers and salts is possible within the specific chemical
designation.
The placement of drugs listed in this subsection shall remain
in effect until February 18, 2019, unless enacted into law in the Drug Control
Act.
D. Pursuant to subsection D of § 54.1-3443 of the Code of Virginia,
the Board of Pharmacy places the following in Schedule I of the Drug Control
Act:
1. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), its optical,
position, and geometric isomers, salts, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation.
2. 5-methoxy-N-ethyl-N-isopropyltryptamine (5-MeO-EIPT), its
optical, position, and geometric isomers, salts, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers is possible within
the specific chemical designation.
3. 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), its
optical, position, and geometric isomers, salts, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers is possible within
the specific chemical designation.
4. (N-methyl aminopropyl)-2,3-dihydrobenzofuran (MAPDB), its
optical, position, and geometric isomers, salts, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers is possible within
the specific chemical designation.
5. 3,4-tetramethylene-alpha-pyrrolidinovalerophenone (TH-PVP),
its optical, position, and geometric isomers, salts, and salts of isomers
whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation.
6. 4-chloro-alpha-methylamino-valerophenone
(4-chloropentedrone), its optical, position, and geometric isomers, salts, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
7. Synthetic opioids:
a.
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (Methoxyacetyl
fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and
ethers, unless specifically excepted, whenever the existence of these isomers,
esters, ethers, and salts is possible within the specific chemical designation.
b.
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl
fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, unless specifically excepted, whenever the existence of these
isomers, esters, ethers, and salts is possible within the specific chemical
designation.
8. Cannabimimetic agent:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide
(5-fluoro-ADB-PINACA), its salts, isomers, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation.
The placement of drugs listed in this subsection shall remain
in effect until June 12, 2019, unless enacted into law in the Drug Control Act.
E. Pursuant to subsection D of § 54.1-3443 of the Code of
Virginia, the Board of Pharmacy places the following in Schedule I of the Drug
Control Act:
1. 2-(methylamino)-2-phenyl-cyclohexanone (other name:
Deschloroketamine), its optical, position, and geometric isomers, salts, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
2.
2-methyl-1-(4-(methylthio)phenyl)-2-morpholinopropiophenone (other name: MMMP),
its optical, position, and geometric isomers, salts, and salts of isomers
whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation.
3. Alpha-ethylaminohexanophenone (other name:
N-ethylhexedrone), its optical, position, and geometric isomers, salts, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
4. N-ethyl-1-(3-methoxyphenyl)cyclohexylamine (other name:
3-methoxy-PCE), its optical, position, and geometric isomers, salts, and salts
of isomers whenever the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation.
5. 4-fluoro-alpha-pyrrolidinohexiophenone (other name:
4-fluoro-alpha-PHP), its optical, position, and geometric isomers, salts, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
6. N-ethyl-1,2-diphenylethylamine (other name: Ephenidine),
its optical, position, and geometric isomers, salts, and salts of isomers
whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation.
7. Synthetic opioids:
a.
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-1,3-benzodioxole-5-carboxamide
(other name: Benzodioxole fentanyl), its isomers, esters, ethers, salts, and
salts of isomers, esters, and ethers, unless specifically excepted, whenever
the existence of these isomers, esters, ethers, and salts is possible within
the specific chemical designation.
b. 3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methylbenzamide
(other name: U-49900), its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, unless specifically excepted, whenever the
existence of these isomers, esters, ethers, and salts is possible within the
specific chemical designation.
c. 2-(2,4-dichlorophenyl)-N-[2-(dimethylamino)
cyclohexyl]-N-methylacetamide (other name: U-48800), its isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers, and salts is
possible within the specific chemical designation.
8. Central nervous system stimulants:
a. Methyl 2-(4-fluorophenyl)-2-(2-piperidinyl)acetate (other
name: 4-fluoromethylphenidate), including its salts, isomers, and salts of
isomers.
b. Isopropyl-2-phenyl-2-(2-piperidinyl)acetate (other name:
Isopropylphenidate), including its salts, isomers, and salts of isomers.
The placement of drugs listed in this subsection shall remain
in effect until August 21, 2019, unless enacted into law in the Drug Control
Act.
F. Pursuant to subsection D of § 54.1-3443 of the Code of
Virginia, the Board of Pharmacy places the following in Schedule I of the Drug
Control Act:
1. Research chemicals:
a. 2-(ethylamino)-2-phenyl-cyclohexanone (other name:
deschloro-N-ethyl-ketamine), its optical, position, and geometric isomers,
salts, and salts of isomers, whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation.
b. 3,4-methylenedioxy-N-tert-butylcathinone, its optical,
position, and geometric isomers, salts, and salts of isomers, whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation.
c. 4-fluoro-N-ethylamphetamine, its optical, position, and
geometric isomers, salts, and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the specific chemical
designation.
d. Beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other
name: bk-2C-B), its optical, position, and geometric isomers, salts, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation.
2. Synthetic opioids:
a.
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-butenamide (other name: Crotonyl
fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, unless specifically excepted, whenever the existence of these
isomers, esters, ethers, and salts is possible within the specific chemical
designation.
b. 2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)
cyclohexyl]-N-methylacetamide (other name: U-51754), its isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers, and salts is
possible within the specific chemical designation.
c.
N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
4-phenylfentanyl), its isomers, esters, ethers, salts, and salts of isomers,
esters, and ethers, unless specifically excepted, whenever the existence of
these isomers, esters, ethers, and salts is possible within the specific
chemical designation.
The placement of drugs listed in this subsection shall
remain in effect until December 12, 2019, unless enacted into law in the Drug
Control Act.
VA.R. Doc. No. R18-5437; Filed April 13, 2018, 3:10 p.m.